<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743794</url>
  </required_header>
  <id_info>
    <org_study_id>1008</org_study_id>
    <nct_id>NCT01743794</nct_id>
  </id_info>
  <brief_title>Continuous Wound Infusion in Lumbar or Thoracic Surgery</brief_title>
  <official_title>Efficacy of Continuous Wound Infusion in Major Lumbar and Thoracic Spine Surgery : A Randomised, Double-blinded, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction : Spine surgery is responsible for intense postoperative pain that can be&#xD;
      treated by an analgesia multimodal approach (IV analgesic infusion and local anesthesia).&#xD;
      Continuous wound infiltration is an efficient and simple technique with few adverse effects&#xD;
      yet very few studies have investigated its potential use in spine surgery. Our randomised,&#xD;
      controlled, double-blinded trial aims to evaluate efficacy of continuous wound infiltration&#xD;
      after major spine surgery.&#xD;
&#xD;
      Methods : After written consent is obtained, the surgeon inserts, at the end of surgery, a&#xD;
      multiholes catheter under muscular layers. Patients are randomised in two groups : The&#xD;
      &quot;treated group&quot; receives ropivacaine 0.2% infusion (bolus of 10 milliliters (mL) followed by&#xD;
      8 mL/h continuous infusion during 48 hours) and the &quot;control group&quot; receives saline solution&#xD;
      (0.9%). In addition, all patients receive patient-controlled intra-venous morphine analgesia.&#xD;
      The investigators hypothesize that the &quot;treated group&quot; will consume morphine less than the&#xD;
      &quot;control group&quot;.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>morphine consumption</measure>
    <time_frame>48 hours after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of patients in need of morphine in post surgery monitoring room</measure>
    <time_frame>1 hour after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morphine consumption in post surgery monitoring room</measure>
    <time_frame>1 hour post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>consumption of morphine</measure>
    <time_frame>72 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global self appreciation of pain management</measure>
    <time_frame>at 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time required for post surgery functional recovery</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects of morphine</measure>
    <time_frame>72 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization delay</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>asked bolus divided by delivered bolus</measure>
    <time_frame>until 72 hours after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score for pain intensity</measure>
    <time_frame>until 72 hours after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Lumbar Spine Surgery</condition>
  <condition>Thoracic Spine Surgery</condition>
  <arm_group>
    <arm_group_label>ropivacaine 0.2%, wound infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>saline solution 0.9%, wound infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>wound infusion, 0.2%, bolus 10mL followed by 8 mL/h infusion</description>
    <arm_group_label>ropivacaine 0.2%, wound infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline solution 0.9%</intervention_name>
    <description>wound infusion, 0.9%, bolus 10mL followed by 8 mL/h</description>
    <arm_group_label>saline solution 0.9%, wound infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adults&#xD;
&#xD;
          -  &gt; 18 years&#xD;
&#xD;
          -  Physical status score I, II or III (American Society of Anesthesiologists)&#xD;
&#xD;
          -  lumbar or thoracic spine surgery with arthrodesis through posterior only approach&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  beneficiary of social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  vulnerable persons according to law&#xD;
&#xD;
          -  scoliosis surgery&#xD;
&#xD;
          -  local anesthetic allergia&#xD;
&#xD;
          -  contraindication to ketamine, acetaminophene, nefopam, non steroidal anti&#xD;
             inflammatory, ropivacaine, morphine, droperidol&#xD;
&#xD;
          -  long term anti platelet aggregants&#xD;
&#xD;
          -  inability to comply to protocol requirements&#xD;
&#xD;
          -  psychiatric disorders or cognitive disabilities&#xD;
&#xD;
          -  chronic pain or long term opioids consumption&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  obesity (BMI &gt; 30)&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital, Departement of Anesthesia and Intensive Care</name>
      <address>
        <city>Grenoble</city>
        <state>Rhone Alpes</state>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>May 9, 2012</study_first_submitted>
  <study_first_submitted_qc>December 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>December 5, 2012</last_update_submitted>
  <last_update_submitted_qc>December 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm, Dissecting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

